Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 9/20 | 0.74 |
| ▸ | ATP1B1 | P05026 | 9/20 | 0.74 |
| ▸ | ATP1A3 | P13637 | 9/20 | 0.74 |
| ▸ | ATP1B2 | P14415 | 9/20 | 0.74 |
| ▸ | ATP1A2 | P50993 | 9/20 | 0.74 |
| ▸ | ATP1B3 | P54709 | 9/20 | 0.74 |
| ▸ | FXYD2 | P54710 | 9/20 | 0.74 |
| ▸ | ATP1A4 | Q13733 | 9/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.74 |
| ▸ | AR | P10275 | 1/20 | 0.74 |
| ▸ | ZFP91 | Q96JP5 | 1/20 | 0.74 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.61 |
| ▸ | ATP12A | P54707 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7286202 | 1.00 | ATP1A1 (0.74) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL12057551 | 1.00 | ATP1A1 (0.74) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL7286487 | 1.00 | ATP1A1 (0.74) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL27272363 | 1.00 | ATP1A1 (0.74) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL15101776 | 1.00 | ATP1A1 (0.74) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL12038720 | 1.00 | ATP1A1 (0.74) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL3364229 | 1.00 | ATP1A1 (0.74) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL7279978 | 0.89 | ATP1A1 (0.59) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL7279990 | 0.89 | ATP1A1 (0.59) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL7287032 | 0.89 | ATP1A1 (0.59) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| EP-0576915-B1 | cyclopentanperhydrophenanthren-17beta-(3-furyl)-3-derivatives and pharmaceutical compositions comprising same for the treatment of cardiovascular disorders | SIGMA TAU IND FARMACEUTI (IT) | 1997-04-16 | — | — | EP | disclosed |
| US-5593982-A | SUCH AS HEART FAILURE AND HYPERTENSION | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1997-01-14 | — | — | US | disclosed |
| EP-0590489-B1 | New cyclopentanperhydrophenanthren-17beta-(hydroxy or alkoxy)-17alpha-(aryl or heterocyclyl)-3beta-derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same | SIGMA TAU IND FARMACEUTI (IT) | 1996-12-11 | — | — | EP | disclosed |
| US-5432169-A | Cyclopentanperhydrophenanthren-17β-(3-furyl)-3-derivatives and pharmaceutical compositions comprising same for the treatment of cardiovascular disorders | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1995-07-11 | — | — | US | disclosed |
| EP-0590489-A2 | New cyclopentanperhydrophenanthren-17beta-(hydroxy or alkoxy)-17alpha-(aryl or heterocyclyl)-3beta-derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1994-04-06 | — | — | EP | disclosed |
| EP-0576915-A2 | cyclopentanperhydrophenanthren-17beta-(3-furyl)-3-derivatives and pharmaceutical compositions comprising same for the treatment of cardiovascular disorders | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1994-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | ATP1A1 3221/4885ATP1B1 2968/4885ATP1A3 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.